title: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes mellitus. Dr. Hertzel Gerstein in an interview with Dr. Roman Jaeschke.
authors.forename: Hertzel
authors.initials: H
authors.lastname: Gerstein
authors.forename: Roman
authors.initials: R
authors.lastname: Jaeschke
mesh_terms: D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000401:mortality; D005960:Glucosides / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome
chemical_list: D001559:Benzhydryl Compounds; D005960:Glucosides; D007004:Hypoglycemic Agents; C570240:empagliflozin